The Recall Desk
LowFDA (Drugs)·D-1226-2014·Announced 2014-04-16

Hospira Recalls Demerol Ampoules Due to Missing Container Labels

Hospira Inc. is recalling 237,850 ampoules of Demerol (meperidine HCL) because the immediate container labels are missing. The recall is nationwide.

What this means for you

Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.

Our severity reasoning: The FDA classified this as a Class III recall, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences. The issue is a packaging/labeling defect without reported injuries.

Plain-English summary

Hospira Inc. is recalling 237,850 ampoules of Demerol, meperidine HCL Injection USP, 25 mg/0.5 mL (50 mg/mL). The product is identified by NDC 0409-1203-01 and Lot 221303A, with an expiration date of October 1, 2014. The recall is being conducted nationwide.

The recall was initiated because the ampoules are missing the immediate container label. This labeling defect prevents the identification of the product on the immediate container.

The U.S. Food and Drug Administration has classified this recall as Class III, which indicates that use of or exposure to the violative product is not likely to cause adverse health consequences. Consumers and healthcare providers should check their inventory for this specific lot and NDC number and stop using the affected ampoules if found.

The recalled product

Product
Demerol, meperidine HCL Inj. USP, 25 mg/0.5 mL (50 mg/mL), 0.5 mL ampoules, Rx only, NDC 0409-1203-01, Hospira, Inc., Lake Forest, IL.
Manufacturer
Hospira Inc.
Affected units
237,850

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot: 221303A
  • 1OCT2014

Distribution

Distributed nationwide across the United States.